| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| UroGen Pharma Ltd. | UGN-103 - (UTOPIA) | Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | NDA Filing | Ongoing | Intravesical | Oncology |
| UroGen Pharma Ltd. | UGN-102 - (ATLAS) | Non-Muscle-Invasive Bladder Cancer | NDA Filing | Ongoing | Intravesical | Oncology |
| UroGen Pharma Ltd. | UGN-102 - (home instillation study) | Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) | Phase 3 | Ongoing | Intravesical | Oncology |
| UroGen Pharma Ltd. | UGN-102 - (OPTIMA II) | Non-Muscle-Invasive Bladder Cancer | Phase 2b | Data Released | Intravesical | Oncology |
| UroGen Pharma Ltd. | RTGel in combination with BOTOX | Overactive Bladder (OAB) | Phase 2 | Trial Discontinued | Intravesical | N/A |
| Valneva SE | IXCHIQ (VLA1553-303) | Chikungunya vaccine | BLA Filing | Withdrawn | Subcutaneous | N/A |
| Valneva SE | IXCHIQ (VLA1553-303) | Chikungunya vaccine | BLA Filing | Withdrawn | Subcutaneous | N/A |
| Valneva SE | VLA1553-321 - (Adolescents trial) | Chikungunya Vaccine for adolecents | sNDA Filing | Data Released | Subcutaneous | N/A |